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doi:10.1016/j.ejvs.2009.01.012Abstract Objectives: This study aimed to determine whether the plasma levels of matrix me-
talloproteinases (MMPs)-2 and -9 and their specific inhibitors (tissue inhibitors of metallopro-
teinases (TIMPs-1 and -2)) were altered in patients with symptomatic and asymptomatic,
severe, recurrent carotid artery stenosis.
Patients: Fifty-two patients (out of a total of 621) who had undergone successful carotid artery
endarterectomy (CEA) between 1999 and 2003 and developed recurrent carotid artery stenosis
(70%) were included in the study. Restenosis was symptomatic in 23 patients and asymptom-
atic in 29 patients.
Methods: Recurrent carotid artery stenosis was classified based on presentation, and as earlye
intermediate (6 months to 3 years) or late (>3 years). A detailed clinical history was taken and
two blood samples were drawn from each patient to determine plasma levels of MMPs and
TIMPs along with other biological parameters. Recurrent stenosis was confirmed with
computed tomographic angiography.
Results: Patients with symptomatic restenosis had significantly (p< 0.001) higher active MMP-2
and -9 plasma values and significantly (p< 0.001) lower TIMP-1 and -2 plasma values when
compared to patients with asymptomatic restenosis. Plasma concentrations of active MMPs
were higher and TIMPs lower in patients affected with late recurrent stenosis as compared
to earlyeintermediate restenosis (p< 0.001). No differences were recorded in latent MMP
plasma values. Multivariate analysis showed that active MMP-2 and -9 were independent
predictors of late recurrent carotid artery stenosis (p< 0.03 and p< 0.001, respectively).
Conclusions: Higher plasma concentrations of active MMP-2 and -9 were associated with an
increased risk of carotid restenosis with plaque recurrence.
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ty for Vascular Surgery. PublisheThe incidence of recurrent stenosis after carotid endarter-
ectomy (CEA) varies from 10% to 25%,1e3 but symptoms occur
in 0.6e3.6% of patients.4e6 Previous studies have concludedd by Elsevier Ltd. All rights reserved.
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generally benign.5,7 Present data indicate that 15 years after
a successful CEA, one-third of the patients can be expected
to develop recurrent carotid artery disease, one-half of
whom can be expected to suffer from a recurrent ischaemic
event.8,9 Although no true consensus exists with regards to
the natural history of these lesions, and their treatment
remains controversial, re-operation is considered necessary
in 1e8% of cases.1,10 It is accepted that re-operation for
significant recurrent carotid artery stenosis is indicated for
patients with symptomatic disease, but several authors have
also recommended re-operation for asymptomatic patients
with >80% carotid artery restenosis.3
The timing and symptoms of carotid artery restenosis are
of biological and clinical importance. Early restenosis is
marked by the accumulation of smooth muscle cells and
fibrous tissue and late recurrence by increased macrophage
infiltration, calcification and a lipid core, thus resembling
primary plaques.11 Both early and late symptomatic rest-
enotic plaques are associated with high macrophage infil-
tration and a large lipid core.11 These processes involve
extensive reorganisation of the extracellular matrix, which
is regulated through a balance between matrix metal-
loproteinases (MMPs) and the tissue inhibitor of metal-
loproteinases (TIMPs). MMPs e a family of zinc-containing
enzymes, secreted as inactive precursors e can degrade
the components of the vascular extracellular matrix.12,13
MMP-2 and -9 belong to the MMP gelatinase family and
efficiently degrade type IV collagen e the major structural
component of the basement membrane. Endogenous TIMPs
regulate MMP activity.12 TIMP-1 inhibits the activity of all
the active MMPs, with a particular affinity for MMP-1, -2, -3
and -9,12 and it is the more widely distributed of the TIMPs.
TIMP-2 selectively limits MMP-2 activity.14
This study tested the hypothesis that alterations in
plasma MMP-2 and -9 and their specific inhibitors (TIMP-1
and -2) during follow-up may predict risk for severe recur-
rent carotid artery stenosis.Patients and Methods
Between January 1999 and December 2003, 621 consecu-
tive patients (526 men and 95 women; mean age: 69 9
years; median age: 68 years; age range: 56e86 years)
presenting at our institution with internal carotid artery
stenosis (70%) underwent CEA. All primary operations
were performed in a standard fashion under general
anaesthesia with electroencephalographic monitoring.
This research was approved by the Committee on
Research Ethics at our institution, in accordance with the
Declaration of Helsinki of the World Medical Association. All
patients included in the study gave informed, written
consent.
The patients were followed up at 4 and 6 months
postoperatively, and at 6-month intervals thereafter, by B-
mode ultrasonography and colour imaging (Acuson 128 XP/
4 with a 7.5 MHz probe; Acuson Corp., Mountain View, CA,
USA). B-mode ultrasonography and colour imaging were
used to assess the presence of recurrent stenosis. The peak
systolic velocities of the internal carotid artery
>230 cm s1 were used to diagnose haemodynamicallysignificant stenosis 70%.15 An end-diastolic velocity
>100 cm s1 was also used when clinical or technical
factors aroused concern that the internal carotid artery
peak systolic velocity may not be representative of the
extent of disease.15 The recurrent stenotic plaque was
defined as uniformly anechogenic, predominantly hypo-
echogenic, predominantly echogenic or uniformly echo-
genic, according to the Gray-Weale scale. The luminal
surface of the plaque was also defined as regular, irregular
with a recess between 0.4 and 2 mm in depth and width or
irregular with a recess >2 mm in depth and width. Recur-
rent stenosis was considered to be present only if the
abnormality detected by B-mode ultrasonography and
colour imaging was not detected on the first immediate
postoperative examination and if it persisted for at least
two examinations performed within 6 months of the orig-
inal examination. B-mode ultrasonography and colour-
imaging findings consistent with 70% stenosis were vali-
dated with computed tomographic angiography (CTA)
according to the standards proposed by the North Amer-
ican Symptomatic Carotid Endarterectomy Trial (NAS-
CET).16 Briefly, CTA axial images, both contrast and non-
contrast, were used for measurements. Coronal and
sagittal multiplanar reformats were used to identify the
carotid orientation to ensure true cross-sectional
measurements in all of the evaluated arteries. These
measurements were verified with measures from reformats
to ensure accuracy in obtaining the narrowest diameter in
a true cross-sectional plane. Special attention to calcified
high-density regions of the plaque was reinforced with
extra-windowing and contrast modification.
In the presence of recurrent carotid artery stenosis
>70%, a complete history was taken, and physical and
neurological examinations were carried out by the neurol-
ogists. Focal cerebral ischaemic events were defined as
a transient ischaemic attack (TIA), amaurosis fugax, central
retinal artery occlusion and minor (defined as a clinical
syndrome of rapidly developing signs or symptoms of focal
loss of cerebral function of vascular origin lasting >24 h and
not leading to a handicap or significant impairment (modi-
fied Rankin scale <3)17 in the activities of daily living) and
major stroke (defined as a clinical syndrome of rapidly
developing signs or symptoms of focal loss of cerebral
function of vascular origin lasting >24 h and leading to
a handicap or significant impairment (modified Rankin scale
>3)17 in the activities of daily living). The patients with
recurrent carotid stenosis were then stratified into
asymptomatic and symptomatic groups and, based on the
recurrence interval, the recurrent carotid artery stenosis
was classified as earlyeintermediate (6 months to 3 years)
or late (>3 years).
At carotid artery restenosis confirmation, or within
a median period of 8 days (mean: 7 4 days; median:
8 days; range: 4e16 days) after a focal cerebral ischaemic
event, two blood samples were drawn from each patient to
determine plasma levels of MMPs and TIMPs and other
biological parameters. Risk factors and associated diseases
were also documented for each patient, along with the use
of aspirin (100 mg per day), ticlopidine (250 mg per day) or
lipid-lowering drugs. The risk factors included tobacco use,
diabetes (insulin-dependent or -independent), cardiac
disease (prior myocardial infarction, stable or unstable
Table 1 Demographics, clinical and biological
characteristics
Asymptomatic Symptomatic
Patients, n (%) 29 (56) 23 (44)
Age, mean SD 73 5 75 5
Gender, M/F 10/19 9/14
Medical co-morbidconditions
Active tobacco use, n (%) 13 (45) 13 (56)
Hypertension, n (%) 15 (52) 14 (61)
Diabetes, n (%) 6 (21) 7 (30)
Ischaemic heart
disease, n (%)
10 (34) 8 (35)
Renal disease, n (%) 4 (14) 3 (13)
Pulmonary disease, n (%) 2 (7) 2 (9)
Obesity, n (%) 4 (14) 3 (13)
Coagulopathy, n (%) 1 (3) 1 (4)
Total cholesterol,
mmol l1 SD
5 1 5 1
LDL-cholesterol,
mmol l1 SD
4 1 4 1
HDL-cholesterol,
mmol l1 SD
1 2 1 2
Non-fasting triglyceride,
mmol l1 SD
4 1 4 1
Recurrent stenosispresentation
Earlyeintermediate
(6 months to 3 years),n (%)
12 (41) 9 (39)
Late (>3 years), n (%) 17 (59) 14 (61)
Medical treatments
Angiotensin-converting
enzyme inhibitors, n (%)
12 (41) 11 (48)
Ca2þ antagonists, n (%) 10 (34) 8 (35)
b-Blockers, n (%) 8 (28) 8 (35)
Nitrates, n (%) 6 (21) 10 (43)
Lipid-lowering drugs, n (%) 15 (52) 9 (39)
Aspirin, n (%) 19 (65) 13 (56)
Ticlopidine, n (%) 16 (55) 12 (52)
SDZ standard deviation.
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hypertension (diastolic blood pressure: 85 mmHg), renal
disease (blood urea nitrogen: >7.1 mmol l1; creatinine
level: >266 mmol l1; creatinine clearance: <50 ml per
min), pulmonary disease (PO2: <60 mmHg; PCO2:
>50 mmHg; pulmonary function tests: <80% of predicted)
and dyslipidaemia (total cholesterol level: 5 mmol l1,
low-density lipoprotein level: 4 mmol l1, high-density
lipoprotein level: 1 mmol l1 and non-fasting triglyceride
level: 1.7 mmol l1). Associated diseases were repre-
sented by obesity (body weight: >20% of ideal) and an
alteration in the coagulation assay. The concomitant pres-
ence of peripheral vascular and/or aneurysmal diseases in
the patients recruited into this study was screened with
ankleebrachial index (ABI) measurements and abdominal
aortic ultrasound.
A control group of 20 age-matched healthy volunteers
(mean age: 65 5 years; median age: 66 years; age
range: 47e79 years) without atherosclerotic lesions
(excluded by carotid and aortic ultrasonography and ABI
measurements) served as a reference for biological
parameters.
Serum matrix metalloproteinase-2 and -9 and their
specific inhibitor activity and immunoassays
Plasma was obtained from EDTA-anticoagulated peripheral
blood samples centrifuged at 4000 g for 10 min, and
stored at 70 C for further analysis. Endogenous plasma
MMP-2 and -9 were assessed using the Biotrak Activity Assay
System (Amersham Biosciences, Little Chalfont, Buck-
inghamshire, UK). This system measures latent enzymes
(pro-form and active forms, but with a relatively low
affinity for TIMP-bound enzymes, as reported by the
manufacturer) after activation using p-aminophenyl-
mercuric acetate, wherein the exclusion of p-amino-
phenylmercuric acetate results in a measurement of the
endogenous free active MMP-2 and -9 fractions. Total MMP-
2 and -9 and TIMP-1 and -2 were determined in EDTA-
plasma samples using an enzyme-linked immunosorbent
assay (ELISA) technique (Amersham Pharmacia), estimating
the ratio of pro-MMP-2 and -9 (or latent) to active enzyme,
therefore, indicating the degree of zymogen activation.
The average coefficient of variance for both activity and
ELISA assays was <5.5%.
Statistical analysis
Data were analysed with a computer software program
(SPSS, version 12.0, for Windows, Basic and Advanced
Statistics, 1989e2003; SPSS Inc., Chicago, IL, USA). Due to
the sample sizes, non-parametric tests were applied.
Continuous variables were analysed with either the Manne
Whitney U test or KruskaleWallis ANOVA, followed by the
Bonferroni post hoc test calculated dividing the p value
(0.05) by the number of paired comparisons made, thus
adjusting for a total of 24 comparisons. Stepwise, logistic
regression analysis adjusted for demographics (age and
gender), medical co-morbid conditions (active tobacco
use, hypertension, diabetes, ischaemic heart disease,
renal disease, pulmonary disease, obesity, coagulopathy,total cholesterol level, LDL-cholesterol level, HDL-choles-
terol level and non-fasting triglyceride level) and medical
treatments (angiotensin-converting enzyme inhibitors,
Ca2þ antagonists, b-blockers, nitrates, lipid-lowering
drugs, aspirin and ticlopidine) was used to test the asso-
ciation between plasma active/latent MMP-2 and -9 and
TIMP-1 and -2 and recurrent carotid artery stenosis
presentation. Odds ratios (ORs) are expressed with 95%
confidence intervals (CI) in this analysis. All results are
expressed as the mean standard deviation. Differences
with a-level of <0.05 were considered statistically
significant.
Results
This study included 389 (63%) patients who underwent
surgery for symptomatic disease and a further 232 (37%)
patients for asymptomatic disease. Overall, 44 (7%)
patients had major complications (stroke and/or
Table 2 Plasma levels of active and latent MMPs and TIMPs in patients affected with recurrent carotid artery stenosis based on
symptoms and recurrence interval
Asymptomatic Symptomatic
Earlyeintermediate
(nZ 12)
Late
(nZ 17)
Earlyeintermediate
(nZ 9)
Late
(nZ 14)
MMP-2
Active 81 19(a) 219 54(b) 410 54(c) 910 96(d)
Latent 1917 333 1835 465 1914 272 1879 270
MMP-9
Active 11 3(e) 24 8(f) 40 6(g) 87 10(h)
Latent 159 45 146 37 155 70 158 69
TIMP-1 807 120(i) 416 104(l) 255 57(m) 113 39(n)
TIMP-2 88 16(o) 48 12(p) 30 4(q) 13 7(r)
All values are expressed as ngml1 SD (standard deviation).
Significance: (a) vs. (b); (a) vs. (c); (a) vs. (d); (b) vs. (c); (b) vs. (d); (c) vs. (d)Z p> 0.0001; (e) vs. (f)Z p> 0.001; (e) vs. (g); (e) vs. (h); (f) vs. (g);
(f) vs. (h); (g) vs. (h)Z p> 0.0001; (i) vs. (l); (i) vs. (m); (i) vs. (n); (l) vs. (l); (l) vs. (n)Z p> 0.0001; (m) vs. (n)Z p> 0.003; (o) vs. (p); (o) vs. (q);
(o) vs. (r)Z p> 0.0001; (p) vs. (q)Z p> 0.001; (p) vs. (r)Z p> 0.0001; (q) vs. (r)Z p> 0.005.
Table 3 Biomarkers associated with late recurrent
carotid artery stenosis in a stepwise logistic regression
model
OR (95% CI) p value
Active MMP-2 1.013 (1.004e1.037) 0.003
Active MMP-9 1.053 (1.030e1.099) 0.001
TIMP-1 0.989 (0.974e1.003) NS
TIMP-2 0.992 (0.983e1.011) NS
NSZ not significant.
528 P. Sapienza et al.myocardial infarction) or died during the 30-day post-
operative period: 36 (9%) symptomatic patients and eight
(3%) asymptomatic patients. During follow-up (mean:
74 9 months; median: 73 months; range: 60e108 months),
15 (2%) patients were lost, 29 (5%) patients died secondary
to ipsilateral stroke, 42 (7%) patients died of unrelated
causes, 11 (2%) patients developed recurrent carotid artery
stenosis ranging between 50% and 69% and 52 (9%) patients
developed recurrent carotid artery stenosis 70% (mean:
74 6%; median: 77%; range: 70e99%) at a mean follow-up
of 45 13 months (median: 42 months; range: 24e96
months).
The latter group was eligible for further analysis. No
other clinical vascular diseases (i.e., abdominal aortic
aneurysm and peripheral vascular disease) affected the
study group. Symptomatic patients had no significant
differences (pZ NS) in demographics, risk-factor-associ-
ated diseases and medical treatments. The demographics,
clinical and biological characteristics of the series are
depicted in Table 1. Among the patients who presented
with symptoms, 12 had a TIA, six had amaurosis fugax, four
had central retinal artery occlusion and one had a minor
stroke.
Plasma MMP-2 and -9 and TIMP-1 and -2 levels
Plasma values of both active and latent MMP-2
(20 5 ngml1 and 902 34 ngml1, respectively) and -9
(5 2 ngml1 and 74 3 ngml1, respectively) of age-
matched healthy volunteers were significantly lower
(p< 0.001) compared to the other groups. On the other
hand, plasma values of TIMP-1 (1234 112 ngml1) and -2
(190 13 ngml1) were significantly higher (p< 0.001) as
compared to the other groups.
Table 2 summarises the active and latent MMPs and TIMPs
plasma levels in patients affected with recurrent carotid
artery stenosis according to symptoms and recurrence
interval. Symptomatic patients had a significantly higher
elevationofactiveMMP-2and -9plasmavaluesas compared to
asymptomatic patients. These alterations were influenced by
the interval of recurrence (earlyeintermediate or late).Plasma values of active MMPs were, in fact, significantly
higher in patients affected with late recurrent stenosis as
compared to earlyeintermediate restenosis. No significant
alterations were recorded for latent MMP release. Symptom-
atic patients had significantly lower plasma values of TIMP-1
and -2, andthesealterationswereassociatedwith the interval
of recurrence. Plasmavalues ofTIMPswere significantly lower
inpatients affectedwith late recurrent carotid artery stenosis
as compared to earlyeintermediate restenosis.
After stepwise logistic regression analysis, active MMP-2
and -9 were the only variables that remained in the model
as independent predictors of late recurrent carotid artery
stenosis (Table 3).
Discussion
Principally, our study found that, independent from its
pathogenesis and clinical presentation, carotid plaque
recurrence may be indicated by an elevation of MMPs, with
late carotid artery restenosis having higher plasma MMPs
than earlyeintermediate plaques. At an early stage of
carotid artery restenosis, MMPs control extracellular matrix
degradation and the release of matrix-degrading metal-
loproteinases, including MMP-2 and -9, which facilitate
intimal remodelling.18,19 These lesions are similar to those
reported in experimental studies of intimal hyperplasia in
animal vascular injury models,20 in which a marked
increase in matrix expression occurs even after cell
MMP and TIMP Alterations in Recurrent Carotid Artery Stenosis 529proliferation has subsided. For carotid artery restenotic
lesions that are similar to primary carotid plaques,11 the
release of MMPs increases with a simultaneous decrease of
TIMPs.
In the presence of symptomatic restenosis, the plasma
levels of MMPs increased even more and those observed in
late symptomatic carotid artery restenosis doubled when
compared to earlyeintermediate symptomatic carotid
artery restenosis. Conversely, the release of the specific
inhibitors was higher in earlyeintermediate lesions
compared to late recurrence. Although the number of
patients included in our study was limited e thus dimin-
ishing the strength of our conclusions, at least in part e
stepwise logistic regression analysis confirmed the strong
independence from the other confounders of plasma active
MMP-2 and -9 as risk indicators for late recurrent carotid
artery stenosis, thus supporting our previous observation in
primary carotid artery stenosis.21
We hypothesise that growth factors and cytokines,
which are also present in restenotic lesions, may up-
regulate the release of MMPs and down-regulate the
release of TIMPs, as occurs in primary atherosclerotic
carotid plaques. In our previous studies,22,23 we demon-
strated that in primary atherosclerotic carotid plaques
basic fibroblast growth factor (bFGF), platelet-derived
growth factor (PDGF) and tumour growth factor (TGF-b1)
are responsible for the dysregulation in the release,
activity and expression of MMPs and TIMPs. We believe
that the interactions between growth factors, cytokines
and MMPs and their natural inhibitors may provoke an
unstable restenotic plaque either in the earlyeinterme-
diate or late period.
The clinical importance of our study lies in the fact that,
in the future, plasma-level alterations of MMPs may signal
the need for re-intervention in order to reduce the risk of
recurrent cerebral ischaemia. However, much further
research and validation is necessary before these
biomarkers can be proposed as specific and sensitive tests.
At present, no conclusive data are present in the literature
with respect toMMPandTIMPalterations. In some studies,24,25
MMP markers seem to be able to detect unstable plaques or
intra-stent stenosis, but, in others, MMPs are not specific and
sensitive tools, with plasma levels being similar in symptom-
atic and asymptomatic patients.26,27 Furthermore, to be
useful, these biomarkers should highlight the appropriate
time-window in which an intervention would be efficacious.
A limitation of our study was that the time between
symptom occurrence and blood analysis had a median of
8 days. This delay might have influenced our results.
However, several authors28,29 have recently demonstrated
that MMPs have a peak in the first 48e72 h after the onset
of neurological symptoms and are strongly associated with
neurological deterioration.
In conclusion, increases in plasma MMP-2 and -9 after
CEA is associated with a higher risk of recurrent carotid
artery stenosis, thus representing a potential future test for
patient surveillance.Conflict of Interest
None.Funding
None.
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